



CLINICAL EVIDENCE

Fesia products – Summary of the evidence

November 2020



A single-blind randomized study with 16 post-acute patients held in Belgrade (Serbia) showed that:

- Fesia Walk combined with conventional rehabilitation is more effective on walking speed, mobility of the lower extremity, balance disability and acti-

- vities of daily living compared to a conventional rehabilitation program only.
- Fesia Walk is effective both in acute and chronic stroke patients withs stroke related foot drop.

(Dujović, et al., 2017)

A usability study carried out with 10 patients in a clinical environment in Pamplona (Spain) showed that:

- It is feasible to include surface multi-field technology while keeping the device simple and intuitive for successful integration in common neurorehabilitation programs.
- All the participants were very satisfied with the Fesia Walk device in terms of usability.

(Imatz-Ojanguren, et al., 2019.)

ONGOING: A **clinical trial** with **30 stroke patients** at the Ubarmin Clinic in **Pamplona (Spain)**.

Use case

JM. an 84-year-old male patient has a severe polyneuropathy caused by a paraneoplastic syndrome, which produced an absence of motor capacity in the muscles below the knee. After 6 weeks of treatment with Fesia Walk, JM. can activate his muscles voluntarily, has increased his walking speed by 30% and has stopped using his walking stick. Fesia Clinic, San Sebastian, Spain.



Studies carried out in Belgrade (Serbia) with stroke patients showed that:

- Multi-field electrodes provide the desired level of selectivity and can be used for generating a functional grasp both in the clinical and home environments. (Malešević, et al., 2012.)
- Combining the performance of multi-field electrodes (increased selectivity and facilitated positioning) with surface-distributed low-frequency asynchronous stimulation (decreased fatigue), as Fesia Grasp does, improves FES applications. (Maneski, et al., 2013.)
- The use of multi-field electrodes resulted in fully functional and reproducible palmar and lateral grasps similar to healthy-like grasps. (Popović-Maneski, et al., 2013.)

A doctoral thesis developed by Dr. Imatz-Ojanguren with stroke patients in Pamplona (Spain) showed that:

Asynchronous stimulation (used in Fesia Grasp) resulted in lower perceived deep discomfort than synchronous stimulation and affected its efficacy. (Imatz-Ojanguren, et al., 2013.)

ONGOING: A clinical study with 15 patients with acquired brain injury in Mondragon (Spain).

Use case

PL. a 69-year-old female patient suffered an ischemic stroke a year ago, which produced severe hemiplegia, with serious impairment of the hand function. After 10 1-hour sessions of treatment with Fesia Grasp, PL. can move her fingers selectively, has increased her grasping strength by 21% and is beginning to use her upper limb in daily living activities, such as drinking from a glass. *Fesia Clinic, San Sebastian, Spain.*





CLINICAL EVIDENCE

Fesia products – Summary of the evidence

November 2020



Some of the **effects** that have been observed are:

- → 38,7% increase in gait speed (Sabut., et al., 2010)
- Improvement in neurophysiological indicators. (Sabut, et al., 2010)
- Increased dorsal flexion and swing phase time. (Nolan, et al., 2015)
- 56,5% increase in dorsiflexor muscles strength. (Sabut, et al., 2011)
- 38,3% decrease in plantar flexor muscles spasticity. (Sabut, et al., 2011)
- Decreased joint pain. (Street, et al., 2018)
- Biomechanical improvements in the least affected leg and in arm swing angle. (Danino, et al., 2013. Chou, et al., 2014)

"Current evidence on the safety and efficacy (in terms of improving gait) of FES for drop foot of central neurological origin appears adequate to support the use of this procedure."

NICE National Institute for Health and Care Excellence

"FES can have a positive orthotic effect, particularly for gait speed and physiological cost index, in patients who were in the chronic stage of stroke recovery."





Some of the **effects** that have been observed are:

- Improvement of motor function (differences up to 27,2 points in Fulg-Meyer Assessment) and use of the paretic arm. (Cerda, et al., 2017)
- Activities of daily living (measured with the Barthel Index). (Nakipoglu Yuzer, et al., 2017)
- Functionality (differences up to 48% in the Box and Block test). (Marquez-Chin, et al., 2017)
- Range of motion in flexion and extension movements of wrist and fingers. (Yildizgören, et al., 2014)
- 56% decrease in wrist and finger flexor muscles spasticity. (Ring, et al., 2005)
- Joint pain reduction. (Malhotra, et al., 2013)

Combinable with:

Botu	linum	toxin

Action observation + Brain computer Interface







"FES targeted at the wrist and forearm muscles should be considered to reduce motor impairment and improve function" [Evidence Level: Early-Level A; Late-Level A].



"There is strong evidence that FES treatment improves upper extremity function" [Evidence Level: 1a]



Canadian Partnership for Stroke Recovery